2026 ICD-10-CM Diagnosis Code T45.522APoisoning by antithrombotic drugs, intentional self-harm, initial encounter
T45.522A is a billable ICD-10-CM diagnosis code for poisoning by antithrombotic drugs, intentional self-harm, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 917 through 918. Coders also document this condition as intentional prostaglandin overdose. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under External cause codes: intent of injury, self-harm; External cause codes: poisoning by drug; and Poisoning by drugs, initial encounter.
Code Identity
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Intentional prostaglandin overdose
- Intentional prostaglandin poisoning
- Prostaglandin overdose
Coding GuidelinesGuidance
When coding a poisoning or reaction to the improper use of a medication (e.g., overdose, wrong substance given or taken in error, wrong route of administration), first assign the appropriate code from categories T36-T50. The poisoning codes have an associated intent as their 5th or 6th character (accidental, intentional self-harm, assault and undetermined). If the intent of the poisoning is unknown or unspecified, code the intent as accidental intent. The undetermined intent is only for use if the documentation in the record specifies that the intent cannot be determined. Use additional code(s) for all manifestations of poisonings.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified (T45). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Epoprostenol
a prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. it is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. the sodium salt has been also used to treat primary pulmonary hypertension (hypertension, pulmonary).Receptors, Epoprostenol
cell surface receptors for epoprostenol. they are coupled to heterotrimeric g-proteins.Ticlopidine
an effective inhibitor of platelet aggregation commonly used in the placement of stents in coronary arteries.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
| Substance | Accidental | Self-harm | Assault | Undetermined | Adverse Effect | Underdosing |
|---|---|---|---|---|---|---|
| Antithrombotic | T45.521 | T45.522 | T45.523 | T45.524 | T45.525 | T45.526 |
| Epoprostenol | T45.521 | T45.522 | T45.523 | T45.524 | T45.525 | T45.526 |
| Indobufen | T45.521 | T45.522 | T45.523 | T45.524 | T45.525 | T45.526 |
| Prostacyclin | T45.521 | T45.522 | T45.523 | T45.524 | T45.525 | T45.526 |
| Prostaglandin (I2) | T45.521 | T45.522 | T45.523 | T45.524 | T45.525 | T45.526 |
| Prostaglandin (I2)::E1 | T45.521 | T45.522 | T45.523 | T45.524 | T45.525 | T45.526 |
| Prostaglandin (I2)::E2 | T45.521 | T45.522 | T45.523 | T45.524 | T45.525 | T45.526 |
| Prostaglandin (I2)::F2 alpha | T45.521 | T45.522 | T45.523 | T45.524 | T45.525 | T45.526 |
| Ticlopidine | T45.521 | T45.522 | T45.523 | T45.524 | T45.525 | T45.526 |
| Triflusal | T45.521 | T45.522 | T45.523 | T45.524 | T45.525 | T45.526 |
Patient EducationClinical
Poisoning
A poison is any substance that is harmful to your body. You might swallow it, inhale it, inject it, or absorb it through your skin. Any substance can be poisonous if too much is taken. Poisons can include:
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T45.522A to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T45.522AOverview
Is T45.522A (Poisoning by antithrombotic drugs, intentional self-harm) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report poisoning by antithrombotic drugs, intentional self-harm, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character A in T45.522A mean?
The final character A marks the initial encounter: use it while the patient is receiving active treatment for poisoning by antithrombotic drugs, intentional self-harm, such as an emergency visit or first evaluation.
What MS-DRG does T45.522A group to?
When poisoning by antithrombotic drugs, intentional self-harm, initial encounter is the principal diagnosis on an inpatient stay, it groups to MS-DRG 917, 918, with relative weights from 0.8571 to 1.5684 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of T45.522A?
Under the General Equivalence Mappings, poisoning by antithrombotic drugs, intentional self-harm, initial encounter converts to ICD-9-CM 964.2 (poisoning-anticoagulants) and E950.4 (poison-drug/medicin NEC). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
